var data={"title":"Cephalexin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cephalexin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5854?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">see &quot;Cephalexin: Drug information&quot;</a> and <a href=\"topic.htm?path=cephalexin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cephalexin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148610\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Daxbia;</li>\n      <li>Keflex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148611\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cephalex;</li>\n      <li>Dom-Cephalexin;</li>\n      <li>Keflex;</li>\n      <li>PMS-Cephalexin;</li>\n      <li>Teva-Cephalexin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046172\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (First Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046164\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">see &quot;Cephalexin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: Oral: 25 to 50 mg/kg/day divided every 6 or 12 hours; maximum daily dose: 2,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: Oral: 75 to 100 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 4,000 mg/<b>day</b> (Bradley, 2015; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Limited data available: Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg/day once daily or divided into 2 doses; maximum dose: 1,000 mg/dose (Warady [ISPD] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis (group A streptococcal): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: <b>Note:</b> Experts recommend dosing on the higher end of the presented range (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;15 years: Oral: 25 to 50 mg/kg/day divided every 12 hours; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;15 years: Oral: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IDSA recommendation: Infants, Children, and Adolescents: Oral: 20 mg/kg/dose twice daily for 10 days, maximum dose: 500 mg/dose (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo (<i>staphylococcus</i> or <i>streptococcus</i>):</b> Infants, Children, and Adolescents: Oral: 25 to 50 mg/kg/day divided every 6 or 8 hours; maximum dose: 250 mg/dose; continue for at least 7 days, full duration dependent upon clinical response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute (AOM):</b> Infants and Children: Oral: 75 to 100 mg/kg/day divided every 6 hours; maximum dose not established for AOM; usual maximum adult dose for mild to moderate infections: 500 mg/dose and for severe infections: 1,000 mg/dose. <b>Note:</b> Cephalexin is not routinely recommended as an empiric treatment option (AAP [Lieberthal 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections (eg, cellulitis, erysipelas):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &le;15 years: Oral: 25 to 50 mg/kg/day divided every 12 hours, maximum dose: 500 mg/dose; for &beta;-hemolytic streptococcal infections, a duration of 10 days is suggested</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &gt;15 years: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IDSA recommendations: Infants, Children, and Adolescents: Oral: 25 to 50 mg/kg/day divided every 6 hours; maximum dose: 500 mg/dose; continue for at least 5 days or longer depending upon clinical response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis; prophylaxis (dental, oral, or respiratory tract procedures):</b> Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes prior to procedure; maximum dose: 2,000 mg/dose (AHA [Wilson 2007]). <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (AHA [Wilson 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired: <i>S. aureus</i> (methicillin-susceptible), mild infection or step-down therapy:</b> Infants &gt;3 months, Children, and Adolescents: Oral: 75 to 100 mg/kg/day in 3 to 4 divided doses; maximum daily dose: 4,000 mg/<b>day</b> (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 2 months to 2 years: Empiric therapy in febrile patients: 50 to 100 mg/kg/day divided every 6 hours for 7 to 14 days (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &gt;15 years: Uncomplicated cystitis: 500 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoarticular infection (eg, septic arthritis, osteomyelitis); step-down therapy:</b> Infants, Children, and Adolescents: Oral: 100 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 4,000 mg/<b>day</b>; duration of therapy variable, dependent upon clinical response and typically extensive (weeks of therapy); compliance should be monitored (Bradley 2015; <i>Red Book</i> [AAP 2015]); a small (n=11) prospective, open-label pharmacokinetic study reported a median dose of 40 mg/kg/dose every 8 hours (mean age: 7 years; range: 1 to 16 years; dose range: 19 to 51 mg/kg/dose every 8 hours) maintained serum concentrations long enough to meet the pharmacokinetic/pharmacodynamic target for efficacy (T&gt;MIC &ge; 40%) (Autmizguine 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Oral: 250 to 1,000 mg every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo:</b> Oral: 250 mg every 6 hours; continue for 7 days, depending upon clinical response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis (group A streptococcal)</b>: Oral: 500 mg every 12 hours. <b>Note</b>: IDSA recommends a duration of 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections: </b> Oral: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection (uncomplicated cystitis):</b> Oral: 500 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, prophylaxis (dental, oral, or respiratory tract procedures):</b> Oral: 2,000 mg 30 to 60 minutes prior to procedure. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no recommendations in the manufacturer's labeling; the following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 25 to 50 mg/kg/day divided every 6 hours: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 8 hours (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 29 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 12 hours (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 24 hours (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 5 to 10 mg/kg/dose every 24 hours after dialysis (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: 5 to 10 mg/kg/dose every 24 hours (maximum dose: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt; 50 mL/minute: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: 250 to 500 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10: 250 to 500 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 250 mg every 12 to 24 hours; moderately dialyzable (20% to 50%); give dose after dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148585\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daxbia: 333 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keflex: 250 mg, 500 mg, 750 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148569\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046176\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Shake suspension well before use. Take without regard to food. If GI distress, may take with food. Give around-the-clock to promote less variation in peak and trough serum levels.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148604\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule: Store at 25&deg;C (77&deg;F); excursions permitted to 15&ordm;C to 30&ordm;C (59&ordm;F to 86&ordm;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for oral suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Refrigerate after reconstitution; discard after 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046175\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible bacterial infections, including acute otitis media and infections of the respiratory tract, skin and skin structure, bone, and genitourinary tract (FDA approved in pediatric patients [age not specified] and adults); has also been used as alternate therapy for endocarditis prophylaxis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148636\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cephalexin may be confused with cefaclor, ceFAZolin, ciprofloxacin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Keflex may be confused with Keppra, Valtrex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148634\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, confusion, dizziness, fatigue, hallucination, headache </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema multiforme (rare), genital pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastritis, nausea (rare), pseudomembranous colitis, vomiting (rare) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Genital candidiasis, vaginal discharge, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice (rare), hepatitis (transient, rare), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, arthropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Interstitial nephritis (rare) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148592\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cephalexin, other cephalosporins, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148573\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Allergic reactions (eg, rash, urticaria, angioedema,  anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis [TEN]) have been reported. If an allergic reaction occurs, discontinue immediately and institute appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder:  Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Direct Coombs tests:  Positive direct Coombs tests and acute intravascular hemolysis has been reported. If anemia develops during or after therapy, discontinue use and work up for drug-induced hemolytic anemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299003\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148578\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13138&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Cephalexin may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the absorption of Cephalexin. Management: Consider administering oral zinc salts at least 3 hours after cephalexin.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148606\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Peak antibiotic serum concentration is lowered and delayed, but total drug absorbed is not affected. Cephalexin serum levels may be decreased if taken with food. Management: Administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148581\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3017197\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Cephalexin crosses the placenta and produces therapeutic concentrations in the fetal circulation and amniotic fluid (Creatsas 1980). Peak concentrations in pregnant patients are similar to those in nonpregnant patients. Prolonged labor may decrease oral absorption (Griffith 1983; Paterson 1972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046171\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; monitor for signs of anaphylaxis with first few doses; number and type of stools/day for diarrhea </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148572\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148591\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid (90%); delayed in young children and may be decreased up to 50% in neonates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely into most body tissues and fluids, including gallbladder, liver, kidneys, bone, sputum, bile, and pleural and synovial fluids; CSF penetration is poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 6% to 15% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates: 5 hours; Children 3-12 months: 2.5 hours; Adults: 0.5 to 1.2 hours (prolonged with renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% to 100% as unchanged drug) within 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148594\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cephalexin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $69.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (500): $612.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (50): $369.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Daxbia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">333 mg (100): $1,140.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Keflex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $1,043.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $1,043.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (50): $521.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cephalexin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $23.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $28.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cephalexin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $418.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $822.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148597\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acelex (BD);</li>\n      <li>Airex (PH);</li>\n      <li>Alexin (IN);</li>\n      <li>Arlexin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Asef (BD);</li>\n      <li>Avloxin (BD);</li>\n      <li>Axcel (LK);</li>\n      <li>Bloflex (PH);</li>\n      <li>Capxin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cecan (PY);</li>\n      <li>Cefabiotic (ID);</li>\n      <li>Cefacet (FR);</li>\n      <li>Cefacin-M (HK);</li>\n      <li>Cefadal (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Cefadin (EC);</li>\n      <li>Cefadyl (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cefalin (ID, PH);</li>\n      <li>Cefalver (MX);</li>\n      <li>Cefamor (ET, ZW);</li>\n      <li>Cefastad (HK);</li>\n      <li>Ceff (ET);</li>\n      <li>Ceforal (IL);</li>\n      <li>Cefovit (IL);</li>\n      <li>Cefrax (TR);</li>\n      <li>Celexin (ET);</li>\n      <li>Cephalen (SG);</li>\n      <li>Cephalex (DE);</li>\n      <li>Cephalexyl (TH);</li>\n      <li>Cephanmycin (MY, SG);</li>\n      <li>Cephast (ET);</li>\n      <li>Ceporex (AU, BB, BH, BM, BS, BZ, CR, CY, EG, GB, GT, GY, HN, IQ, IR, IT, JM, JO, KW, LB, LY, MX, NI, NZ, OM, PA, PH, PT, QA, SA, SR, SV, SY, TT, VN, YE, ZA);</li>\n      <li>Ceporex Forte (PT);</li>\n      <li>Ceporexin (AR);</li>\n      <li>Ceprax (CO);</li>\n      <li>Ceproex (DO);</li>\n      <li>Ceralin (HR);</li>\n      <li>Cerexin (ZA);</li>\n      <li>Cilex (AU);</li>\n      <li>Erocetin (PY, UY);</li>\n      <li>Falexin (KR);</li>\n      <li>Farmalex (TH);</li>\n      <li>Felexin (ET, LK, MY, TR);</li>\n      <li>Fexin (ZA);</li>\n      <li>Glexil (VN);</li>\n      <li>Glopixin (VN);</li>\n      <li>Ibilex (AU, NZ, TH);</li>\n      <li>Inphalex (ID);</li>\n      <li>Italcefal (EC);</li>\n      <li>Kefacin (BH, CY, EG, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Kefalex (FI);</li>\n      <li>Kefalospes (GR);</li>\n      <li>Kefaxin (GR);</li>\n      <li>Keflex (AE, AT, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CO, CY, DK, EE, ET, GB, GH, GM, GN, GR, GY, IE, JM, JO, KE, KW, LB, LI, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, PE, PH, PK, PL, PT, QA, RO, SA, SC, SD, SE, SL, SN, SR, TH, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Kefloridina (ES);</li>\n      <li>Keforal (AR, BE, FR, IT, NL, VE);</li>\n      <li>Kidolex (TW);</li>\n      <li>Larixin (JP);</li>\n      <li>LC-Lexin (PH);</li>\n      <li>Lecef (LK);</li>\n      <li>Lenocef (ZA);</li>\n      <li>Lexin (AE, BD, JO, PE, QA);</li>\n      <li>Lexipron (ID);</li>\n      <li>Madlexin (ID);</li>\n      <li>Meceta (VN);</li>\n      <li>Medolexin (MY);</li>\n      <li>Monocef (LI);</li>\n      <li>Nafacil-S (MX);</li>\n      <li>Neokef (MY);</li>\n      <li>Nufex (IN);</li>\n      <li>Oracef (CZ);</li>\n      <li>Oralexin (LB);</li>\n      <li>Oriphex (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ospeksyn (UA);</li>\n      <li>Ospexin (AT, BG, BH, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);</li>\n      <li>Ospexina (CO);</li>\n      <li>Paferxin (MX);</li>\n      <li>Palitrex (ID);</li>\n      <li>Pectril (PH);</li>\n      <li>Pharmexin (BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Plecef (LK);</li>\n      <li>Proxicef (HR);</li>\n      <li>Ramoxin (JO);</li>\n      <li>Rancef (AU);</li>\n      <li>Relaxin (PH);</li>\n      <li>Sanaxin (AT);</li>\n      <li>Sef (LI);</li>\n      <li>SEF (TR);</li>\n      <li>Sepexin (IN);</li>\n      <li>Septilisin (AR);</li>\n      <li>Servicef (MX);</li>\n      <li>Servispor (TW);</li>\n      <li>Sialexin (TH);</li>\n      <li>Sofilex (HK, MY, SG);</li>\n      <li>Solulexin (MY);</li>\n      <li>Sorlex (PH);</li>\n      <li>Sporicef (TH);</li>\n      <li>Sporidex (AE, IN, PH);</li>\n      <li>Sporidin (TH);</li>\n      <li>Sporidin AF (TH);</li>\n      <li>Theoflex (LK);</li>\n      <li>Uphalexin (MY, SG);</li>\n      <li>Winlex (TW);</li>\n      <li>Zecef (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP) Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/21873693 /pubmed\" target=\"_blank\" id=\"21873693 \">21873693 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24911394\"></a>Amir LH, Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #4: Mastitis, revised March 2014. <i>Breastfeed Med</i>. 2014;9(5):239-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/24911394/pubmed\" target=\"_blank\" id=\"24911394\">24911394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Autmizguine J, Watt KM, Th&eacute;or&ecirc;t Y, et al. Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections. <i>Pediatr Infect Dis J</i>. 2013;32(12):1340-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/23811740/pubmed\" target=\"_blank\" id=\"23811740\">23811740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26512442\"></a>Berens PD. Breast pain: engorgement, nipple pain, and mastitis. <i>Clin Obstet Gynecol</i>. 2015;58(4):902-914.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/26512442/pubmed\" target=\"_blank\" id=\"26512442\">26512442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergan T, &ldquo;Pharmacokinetic Properties of Cephalosporins,&rdquo; <i>Drugs</i>, 1987, 34 (Suppl 2):89-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/3319507/pubmed\" target=\"_blank\" id=\"3319507\">3319507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Creatsas G, Pavlatos M, Lolis D, Kaskarelis D. A study of the kinetics of cephapirin and cephalexin in pregnancy. <i>Curr Med Res Opin</i>. 1980;7(1):43-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/7428412/pubmed\" target=\"_blank\" id=\"7428412\">7428412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith RS. The pharmacology of cephalexin. <i>Postgrad Med J</i>. 1983;59(Suppl 5):16-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/6364086/pubmed\" target=\"_blank\" id=\"6364086\">6364086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16551765\"></a>Ilett KF, Hackett LP, Ingle B, Bretz PJ. Transfer of probenecid and cephalexin into breast milk. <i>Ann Pharmacother</i>. 2006;40(5):986-989.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/16551765/pubmed\" target=\"_blank\" id=\"16551765\">16551765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8498418\"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. <i>Acta Paediatr Scand</i>. 1981;70(3):285-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/7246123/pubmed\" target=\"_blank\" id=\"7246123\">7246123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/23439909 /pubmed\" target=\"_blank\" id=\"23439909 \">23439909 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paterson ML, Henderson A, Lunan CB, et al, &quot;Transplacental Transfer of Cephalexin,&quot; <i>Clinical Medicine</i>, 1972, 22-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &quot;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. <i>Circulation</i>. 2007;116(15):1736-1754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-pediatric-drug-information/abstract-text/17446442 /pubmed\" target=\"_blank\" id=\"17446442 \">17446442 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13138 Version 201.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F148610\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F148611\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046172\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046164\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148585\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F148569\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046176\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F148604\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046175\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F148636\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148634\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F148592\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148573\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299003\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148578\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F148606\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148581\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3017197\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046171\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148572\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F148591\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F148594\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F148597\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13138|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">Cephalexin: Drug information</a></li><li><a href=\"topic.htm?path=cephalexin-patient-drug-information\" class=\"drug drug_patient\">Cephalexin: Patient drug information</a></li></ul></div></div>","javascript":null}